The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson's ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

A new analysis of data from the PHENIX experiment at the Relativistic Heavy Ion Collider (RHIC) reveals fresh evidence that ...

Spanish drugmaker Grifols has been awarded a $21 million grant from the Michael J Fox Foundation to support a pilot study to ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

Immune globulin (human) is under clinical development by Grifols and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Spanish plasma-based medicines maker Grifols (MCE: GRF) has announced disappointing top-line data from its Phase III PRECIOSA clinical trial evaluating the potential of long-term albumin treatment ...

Heating plasma to the ultra-high temperatures needed for fusion reactions requires more than turning the dial on a thermostat. Scientists consider multiple methods, one of which involves injecting ...

One of their biggest roster weaknesses is the center position, where they lack a strong backup behind Anthony Davis and don't really have the ability to run lineups with another true big man alongside ...

(Bloomberg) -- Most analysts are sticking with their calls to buy Spanish drugmaker Grifols SA as one of the favored picks ... firms that dominate the global business of collecting blood plasma and ...

Brookfield’s pursuit of Grifols formally ended two weeks ago when the private equity firm announced it was shelving a plan to take over the company, which collects blood plasma and turns it into ...

Grifols will produce the plasma-based product at its large manufacturing center in Clayton. The company has invested close to $1 billion at the site since coming to North Carolina in 2011. Hyperimmune ...